Format

Send to

Choose Destination
Curr Opin Infect Dis. 2011 Dec;24(6):586-92. doi: 10.1097/QCO.0b013e32834c630e.

Boron-based drugs as antiprotozoals.

Author information

1
SCYNEXIS Inc., Research Triangle Park, North Carolina, USA. bob.jacobs@scynexis.com

Abstract

PURPOSE OF REVIEW:

Boron-based drugs represent a new class of molecules that have been found to exhibit attractive properties and activities against a number of protozoans causative of neglected tropical diseases.

RECENT FINDINGS:

This review highlights recent advances in discovery of potential treatments for human African trypanosomiasis, malaria and Chagas disease from a class of boron-containing drugs, the benzoxaboroles.

SUMMARY:

Research at several biotechnology companies, sponsored by product development partners (PDPs), has been successful in identifying a novel class of boron-based drugs, the benzoxaboroles, as potential treatments for neglected tropical diseases. This work was based, in part, on the earlier observation of antifungal, antibacterial and anti-inflammatory activities of the benzoxaboroles. The unique properties of boron, namely its ability to reversibly interact with biochemical targets through an empty p-orbital, are important to the success of these new drug candidates. Physicochemical and pharmacokinetic properties of the boron-based compounds are consistent with features required for oral absorption, metabolic stability and low toxicity - all important for progression of this class to clinical trials.

PMID:
22001943
DOI:
10.1097/QCO.0b013e32834c630e
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center